Overview

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Status:
Recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: - To characterize the long-term efficacy of fitusiran as assessed by the frequency of: - Bleeding episodes - Spontaneous bleeding episodes - Target joint bleeding episodes - To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age

Phase:

Phase 3

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Antibodies
Factor VIII